Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Rating) – Equities researchers at Zacks Investment Research issued their Q2 2022 EPS estimates for Reviva Pharmaceuticals in a research note issued on Thursday, May 19th. Zacks Investment Research analyst J. Vandermosten forecasts that the company will earn ($0.31) per share for the quarter. Zacks Investment Research also issued estimates for Reviva Pharmaceuticals’ FY2024 earnings at ($0.54) EPS.
RVPH stock opened at $1.67 on Monday. The firm’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $2.39. The company has a market capitalization of $25.27 million, a P/E ratio of -1.94 and a beta of 0.19. Reviva Pharmaceuticals has a 12 month low of $1.34 and a 12 month high of $5.69.
Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Reviva Pharmaceuticals by 82.7% in the 3rd quarter. BlackRock Inc. now owns 33,470 shares of the company’s stock valued at $136,000 after purchasing an additional 15,152 shares during the period. Geode Capital Management LLC lifted its stake in shares of Reviva Pharmaceuticals by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 76,964 shares of the company’s stock valued at $313,000 after purchasing an additional 9,240 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Reviva Pharmaceuticals in the 4th quarter valued at $27,000. Raymond James & Associates acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $34,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $31,000. 17.27% of the stock is currently owned by institutional investors and hedge funds.
About Reviva Pharmaceuticals (Get Rating)
Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Reviva Pharmaceuticals (RVPH)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.